The European Medicines Agency (EMA) published scientific advice to the Medical Device Coordination Group (MDCG) with regards to the classification of SARS-CoV-2 tests for in vitro diagnostic (IVD) purposes. The advice was requested by the MDCG and published in December 2024. During the pandemic, SARS-CoV-2 tests tended to be classified under the highest risk class D under the regime of the in vitro diagnostic medical devices regulation (IVDR). After the pandemic, associated risk has lessened significantly.
The document provides advice how SARS-CoV-2 tests should currently be considered in light of the classification categories under the IVDR. Manufacturers of the corresponding tests should take the document into account as this will have a major impact on the conformity assessment under the IVDR and the duration of the transitional regime. The document can be accessed in the corresponding section of our website.
EMDN coding
The MDCG issued a number of documents with regards to EMDN coding. MDCG 2021-12, FAQ on the European Medical Device Nomenclature (EMDN), was updated with 18 new questions and answers in revision 1. Furthermore, MDCG 2024-2, Procedures for the updates of the European Medical Device Nomenclature, was updated. In addition, the MDCG issued MDCG 2025-1 to MDCG 2025-3. These include forms for the application of new EMDN codes as well as an overview of changes to the current codes. Should you require help in finding an appropriate code or apply for a new code, please let us know. The document can be accessed in the corresponding section of our website.
Source: EMA, European Commission